Sanofi would transfer selected mature medicines and Manufacturing operations to Cheplapharm in exchange for a 26.4% Equity stake in the pharmaceutical group. Sanofi says the proposed transaction is not expected to affect its 2026 financial guidance, while the Partnership is intended to support established medicines and sharpen its focus on innovation.

Key Highlights

  • Sanofi says the proposed transaction is not expected to affect its 2026 financial guidance.
  • The transferred portfolio includes Lovenox and Clexane, also known as enoxaparin, with the stated scope excluding the United States.
  • Sanofi and Cheplapharm began their collaboration in 2014.

The arrangement would shift responsibility for those Assets to Cheplapharm while giving Sanofi (NASDAQ: SNY) an ownership interest in its European pharmaceutical partner.

Medicines Partnership Sets 2027 Transfer Schedule

The partnership builds on cooperation between the two companies that began in 2014. Sanofi’s transferred portfolio includes Lovenox and Clexane, excluding the United States. Cheplapharm would assume responsibility for manufacturing sites worldwide, with employees continuing under existing employment arrangements and collective agreements. Completion is expected in the third quarter of 2027, subject to employee information and consultation procedures, regulatory approvals and customary closing conditions.

Sanofi Retains 2026 Guidance

Sanofi says the proposed transaction is not expected to change its financial guidance for 2026. The company says the arrangement will allow it to keep concentrating its efforts on innovation while established medicines move into the next stage of their lifecycle. Cheplapharm describes the project as a long-term pharmaceutical and industrial commitment involving Investment in sites and preservation of specialized expertise. Further financial details are expected later.